- Home
- PULM vs NBY Comparison
PULM vs NBY Comparison
Compare PULM & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- NBY
- Stock Information
- Founded
- PULM 2003
- NBY 2000
- Country
- PULM United States
- NBY United States
- Employees
- PULM N/A
- NBY N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- NBY
- Sector
- PULM Health Care
- NBY
- Exchange
- PULM Nasdaq
- NBY Nasdaq
- Market Cap
- PULM 18.3M
- NBY 15.7M
- IPO Year
- PULM N/A
- NBY 2007
- Fundamental
- Price
- PULM $4.89
- NBY $1.75
- Analyst Decision
- PULM
- NBY Strong Buy
- Analyst Count
- PULM 0
- NBY 1
- Target Price
- PULM N/A
- NBY $0.85
- AVG Volume (30 Days)
- PULM 9.6K
- NBY 21.1M
- Earning Date
- PULM 11-07-2025
- NBY 11-06-2025
- Dividend Yield
- PULM N/A
- NBY N/A
- EPS Growth
- PULM N/A
- NBY N/A
- EPS
- PULM N/A
- NBY 0.41
- Revenue
- PULM $369,000.00
- NBY $9,781,000.00
- Revenue This Year
- PULM N/A
- NBY $23.91
- Revenue Next Year
- PULM $134.88
- NBY $32.05
- P/E Ratio
- PULM N/A
- NBY $4.97
- Revenue Growth
- PULM N/A
- NBY 113.47
- 52 Week Low
- PULM $1.96
- NBY $0.46
- 52 Week High
- PULM $10.40
- NBY $4.44
- Technical
- Relative Strength Index (RSI)
- PULM 45.65
- NBY 48.05
- Support Level
- PULM $4.70
- NBY $2.28
- Resistance Level
- PULM $5.19
- NBY $3.30
- Average True Range (ATR)
- PULM 0.15
- NBY 0.64
- MACD
- PULM 0.07
- NBY -0.10
- Stochastic Oscillator
- PULM 44.44
- NBY 10.03
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.